Neuropathic Pain Market Value Strategy, Regional Analysis and Growth Forecast to 2027
Neuropathic Pain Market 2022 Global Neuropathic Pain Market is expected to have a market value of USD 28,778.20 Million by 2027. Rising cases of cancer and technological advancements are driving the market growth. In addition, rising pipeline drugs by the companies for neuropathic pain is one of the major factors contributing to the growth of neuropathic pain. Major Key Players: MRFR recognizes the following companies as the Key Players in the Global Neuropathic Pain Market Value— Abbott, GSK, Sanofi, Pfizer, Eli Lily, AstraZeneca, Johnson and Johnson, Biogen, Inc. Depomed, and Astellas. Segment Analysis Global neuropathic pain management market is segmented, based on Type, Into Peripheral Neuropathy (PN), entrapment neuropathy, trigeminal neuralgia, phantom limb pain (PLP), post herpetic neuralgia (PHN) and post-traumatic neuropathy. The global Neuropathic Pain Market, by indication, is segmented as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, spinal stenos